Lataa...
A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure
BACKGROUND: The Swiss label of oral fingolimod (0.5 mg once daily) requires a 6-hour first dose observation (FDO) including an ECG prior to and 6 hours after the first intake but in comparison to other countries such as Austria, Australia and Canada there are no restrictions regarding the clinical s...
Tallennettuna:
| Julkaisussa: | BMC Pharmacol Toxicol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4405834/ https://ncbi.nlm.nih.gov/pubmed/25889400 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-015-0006-0 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|